Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT07619989·Not applicable·INTERVENTIONAL

Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists

TirzepatideWeight lossRecruiting

Status

Recruiting

Phase

Not applicable

Enrollment

24

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

This is a single-center, randomized, participant-blinded, sham-controlled trial designed to evaluate the adjunctive effect of transcutaneous auricular vagus nerve stimulation (taVNS) in overweight or obese patients who show a suboptimal weight-loss response to incretin receptor agonist therapy. A total of 24 participants will be randomly assigned to receive either taVNS plus tirzepatide 5 mg or sham stimulation plus tirzepatide 5 mg for 12 weeks. The primary objective is to compare the percent change in body weight from baseline to week 12 between the two groups.

Full detailed description

This is a prospective, single-center, randomized, participant-blinded, sham-controlled, parallel-group study conducted at the Department of Endocrinology, Nanjing Drum Tower Hospital. The study will enroll 24 overweight or obese participants with a suboptimal weight-loss response, defined as a body weight reduction of no more than 10% after at least 12 weeks of tirzepatide treatment. Eligible participants will be randomized in a 1:1 ratio to the taVNS plus tirzepatide 5 mg group or the sham stimulation plus tirzepatide 5 mg group for 12 weeks. Before and after intervention, all participants will undergo standardized assessments, including lifestyle questionnaires, anthropometric measurements, body composition analysis, autonomic function evaluation, laboratory testing, and assessment of hepatic steatosis and fibrosis. Autonomic function assessment will include heart rate variability, cardiovascular autonomic reflex tests, sudomotor function, and brain MRI. Liver-related assessments will include FibroTouch and liver MRI. During follow-up, body weight will be monitored weekly by telephone or WeChat, waist circumference, hip circumference, and body composition will be reassessed every 4 weeks, and device use will be monitored through an app to ensure adherence and protocol consistency. The primary endpoint is the between-group difference in percent change in body weight from baseline to week 12. Secondary endpoints include changes in body composition and fat distribution, glucose- and lipid-related metabolic parameters, liver function and hepatic steatosis/fibrosis-related parameters, and autonomic function measures. Exploratory analyses will evaluate changes in brain imaging phenotypes after 12 weeks of intervention.

Interventions

Treatment arms and agents.

DEVICE

transcutaneous auricular vagus nerve stimulation

Participants will receive active transcutaneous auricular vagus nerve stimulation plus tirzepatide 5 mg for 12 weeks. Active stimulation will be delivered to the bilateral cymba conchae, an auricular region innervated by the auricular branch of the vagus nerve. Stimulation will use an intermittent waveform of 15 seconds on and 5 seconds off at 20 Hz, with a pulse width of 0.2 ms. Stimulation intensity will be titrated from 0 mA to a level that produces mild tingling without obvious discomfort, usually 1.0-2.5 mA. Stimulation will be administered twice daily for 30 minutes per session, 5 days per week, for 12 weeks. Tirzepatide will be administered as a subcutaneous injection once weekly.

DEVICE

Sham

Participants will receive sham stimulation in addition to tirzepatide 5 mg for 12 weeks. Sham stimulation will be applied to the bilateral tail of the helix, an auricular site without vagus nerve distribution, whereas active taVNS targets the cymba conchae, which is innervated by the auricular branch of the vagus nerve. The sham group will use the same waveform parameters, stimulation intensity titration, and treatment schedule as the active group, namely twice daily for 30 minutes per session, 5 days per week, for 12 weeks. Tirzepatide will be administered as a subcutaneous injection once weekly.

Timeline

From registration to results.

  1. First posted

    Jun 2, 2026

  2. Study start

    Aug 1, 2026

  3. Primary completion

    Jun 1, 2027

  4. Study completion

    Sep 1, 2027

  5. Results posted

    Not reported

  6. Registry updated

    Jul 31, 2026

Outcomes

What the study measures.

Primary outcomes

Percent Change in Body Weight From Baseline

Time frame · Baseline, 4 weeks, 8 weeks, 12 weeks

Percent change in body weight from baseline to week 12 will be compared between the taVNS plus tirzepatide group and the sham stimulation plus tirzepatide group to evaluate the adjunctive effect of taVNS on weight reduction.

Secondary outcomes

Change in Waist Circumference

Time frame · Baseline, Week 4, Week 8, Week 12

Change in waist circumference from baseline to Week 4, Week 8, and Week 12 will be assessed using standardized anthropometric measurement.

Change in Body Composition and Fat Distribution

Time frame · Baseline, ,Week 4, Week 8, Week 12

Changes in body composition and fat distribution will be assessed by body fat percentage using anthropometric measurements and body composition analysis.

Change in blood glucose

Time frame · Baseline, Week 12

Change in fasting blood glucose from baseline to Week 12 will be assessed using laboratory testing.

Change in Hip Circumference

Time frame · Baseline, Week 4, Week 8, Week 12

Change in hip circumference from baseline to Week 4, Week 8, and Week 12 will be assessed using standardized anthropometric measurement.

Change in Visceral Fat Area

Time frame · Baseline, Week 4, Week 8, Week 12

Change in visceral fat area from baseline to Week 4, Week 8, and Week 12 will be assessed using body composition analysis.

Change in Glycated Hemoglobin

Time frame · Baseline, Week 12

Change in glycated hemoglobin (HbA1c) from baseline to Week 12 will be assessed using laboratory testing.

Change in High-Density Lipoprotein Cholesterol

Time frame · Baseline, Week 12

Change in high-density lipoprotein cholesterol (HDL-C) from baseline to Week 12 will be assessed using laboratory testing.

Change in Low-Density Lipoprotein Cholesterol

Time frame · Baseline, Week 12

Change in low-density lipoprotein cholesterol (LDL-C) from baseline to Week 12 will be assessed using laboratory testing.

Change in Triglycerides

Time frame · Baseline, Week 12

Change in triglycerides from baseline to Week 12 will be assessed using laboratory testing.

Change in Controlled Attenuation Parameter

Time frame · Baseline, Week 12

Change in controlled attenuation parameter (CAP) from baseline to Week 12 will be assessed using transient elastography.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
50 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: 1. Individuals with obesity, or overweight accompanied by at least one weight-related comorbidity (e.g., hypertension or fatty liver disease), who have been receiving tirzepatide therapy for at least 12 weeks and have achieved ≤10% weight loss during treatment; 2. Willingness to provide written informed consent. Exclusion Criteria: 1. Presence of diseases that may substantially affect body weight homeostasis, including Cushing's syndrome, uncontrolled thyroid disease (thyroid-stimulating hormone \>6.0 mIU/L or \<0.4 mIU/L), malignancy, or similar conditions; 2. Use within the past 3 months of medications, other than incretin receptor agonists, that may significantly affect body weight, including glucocorticoids and antipsychotic agents; 3. Skin infection or damage involving the auricular area; 4. Women planning pregnancy in the near future; 5. Contraindications to MRI, such as metallic prostheses or claustrophobia; 6. Diagnosis of diabetes mellitus; Inability to complete the 12-week intervention period for practical reasons, such as frequent business travel or planned travel.

Study locations

1 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Tirzepatide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsTirzepatide trial dashboard →DatabaseTirzepatide database entry →ResearchTirzepatide research guide →